A randomized open-label trial to evaluate the cardiovascular risk in stable renal allograft recipients on a ciclosporin A (CsA) based regimen monitored either by residual expression of nuclear factor of activated T-cells (NFAT) – regulated genes or CsA trough levels
Latest Information Update: 31 Jan 2017
At a glance
- Drugs Ciclosporin (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions
- Acronyms The CIS study
- 04 Apr 2015 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
- 05 Jul 2013 New trial record